Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
about
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsHow to manage aspergillosis in non-neutropenic intensive care unit patientsTreatment and prophylaxis of invasive candidiasisTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsFundament and Prerequisites for the Application of an Antifungal TDM ServiceGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveTriazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatusTherapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage.Voriconazole pharmacokinetics and pharmacodynamics in children.Voriconazole pharmacokinetics in liver transplant recipients.Voriconazole associated torsades de pointes in two adult patients with haematological malignancies.Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyCYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisVoriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.General principles of antimicrobial therapy.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andSerum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyEvaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infectionsClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Human tissue distribution of voriconazole.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Inflammation is associated with voriconazole trough concentrations.Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Epidemiology and treatment approaches in management of invasive fungal infectionsPharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyHow much European prescribing physicians know about invasive fungal infections management?
P2860
Q26771180-EC03B7AE-D54F-454C-8627-765D4D1FADF3Q26999448-6A365352-41E0-443C-BBB9-5D32ABD2FC59Q27001567-09720AF8-3377-4B22-9243-B5D4063169EFQ27009221-CA4E86F6-6081-435A-B008-167CD1B72569Q27025299-4DF8D61D-7A16-4F71-B675-922CDFDA787DQ28085352-08E5B50B-99E8-46A9-95AD-4B0FD2B707F5Q28388806-CE72B98C-D214-456B-ACE1-43303F085539Q28481341-41FC9405-EC13-4CC2-AF33-67BD6C5C410CQ30981299-8459E179-10ED-45FA-920F-52E7665516B2Q33559503-243E1E15-2AB6-4F38-A2B9-E57AE7082EEEQ33573641-CCB7A61C-5E8C-416D-8D5A-C31C1924F69AQ33577291-E3C71C7C-7336-404C-8988-B1AA0C9B51DCQ33613685-D4F84B7D-EE22-4E92-B187-D8DB3D267E27Q33625746-14D9C39A-9A2B-4395-8833-B6D0FBB6002CQ33684379-92AFA0C9-5FE3-4597-850D-3DC2CB3490D2Q33798203-B6C1C147-F446-4BE5-B9CF-33CD18646A25Q33827819-82CB20BC-17E5-424F-A843-F1CAE153A76AQ33849298-5522C41B-2501-4299-8DB4-3DEAE8CEFAAFQ33876645-D5D804ED-9BA5-4F1D-AFE0-AF0D41BB414CQ34020402-D80BCC3F-544D-4425-B14B-03BF010CE7F1Q34045383-6ECEF64D-F017-4E1F-8139-A3D51D56758AQ34138276-D3EAE4DD-0FD0-4E5D-9D28-A416A5708D76Q34150943-CBEE2338-402A-4D3C-BB4E-990F8BA021B7Q34161745-E2BE08C6-0C34-4399-81A0-6E73ABE10EC5Q34309603-C077CDA0-0364-4C86-A9CA-5534D53DA238Q34413393-61FE5AAC-6CDA-43E7-9567-5FF3ED5B8960Q34483712-C3D41A09-8095-4596-BAB9-79B9D9C25636Q34505582-1975E7F7-80A7-40BF-A72D-944046569DE2Q34529318-E36554D6-F39D-4824-B243-424446A014CDQ34532546-22EDBC2C-DB9E-459C-9A14-CDC3498AC42FQ34596313-6BEAC3B7-67E9-46AB-9C8F-892CEBC6324CQ34597394-6672744A-F35D-430B-AD36-846E824D33DCQ34737476-54132A8F-A383-4456-BD20-EB986B88DE07Q34980027-5AAB23DD-3BD8-4AB3-98DB-07537EA208D9Q35026481-EFCBC50E-6AAD-4A3C-B28D-9884DF62D9DAQ35086478-E16EFDB1-286F-4199-9762-B88153AC7004Q35089772-8EC260D9-F689-4E7F-A895-CFE4487F7957Q35105949-2E65C2AF-2738-48B1-ABC8-48EF01B1C0C4Q35114591-BE103C63-56CA-4B96-80D4-7916865B3F2FQ35131938-6AAE335D-73F4-4AFA-AE25-402506A6174F
P2860
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@en
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@nl
type
label
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@en
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@nl
prefLabel
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@en
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@nl
P2093
P2860
P356
P1476
Voriconazole therapeutic drug ...... efficacy and safety outcomes.
@en
P2093
Andres Pascual
Jacques Bille
Oscar Marchetti
Saskia Bolay
P2860
P304
P356
10.1086/524669
P407
P577
2008-01-01T00:00:00Z